VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Identifieur interne : 001D35 ( PubMed/Corpus ); précédent : 001D34; suivant : 001D36VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Auteurs : David S. Siegel ; Meletios Dimopoulos ; Sundar Jagannath ; Hartmut Goldschmidt ; Simon Durrant ; Jonathan L. Kaufman ; Xavier Leleu ; Arnon Nagler ; Fritz Offner ; Thorsten Graef ; Joseph E. Eid ; Jennifer Houp ; Christine Gause ; Scott Vuocolo ; Kenneth C. AndersonSource :
- Clinical lymphoma, myeloma & leukemia [ 2152-2669 ] ; 2016.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bortezomib (administration & dosage), Drug Resistance, Neoplasm, Female, Humans, Hydroxamic Acids (administration & dosage), Male, Multiple Myeloma (drug therapy), Multiple Myeloma (mortality), Multiple Myeloma (pathology), Recurrence, Retreatment, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Bortezomib, Hydroxamic Acids.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Multiple Myeloma.
- mortality : Multiple Myeloma.
- pathology : Multiple Myeloma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Drug Resistance, Neoplasm, Female, Humans, Male, Recurrence, Retreatment, Survival Analysis, Treatment Outcome.
Abstract
The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents.
DOI: 10.1016/j.clml.2016.02.042
PubMed: 27025160
Links to Exploration step
pubmed:27025160Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.</title><author><name sortKey="Siegel, David S" sort="Siegel, David S" uniqKey="Siegel D" first="David S" last="Siegel">David S. Siegel</name><affiliation><nlm:affiliation>Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org.</nlm:affiliation></affiliation></author><author><name sortKey="Dimopoulos, Meletios" sort="Dimopoulos, Meletios" uniqKey="Dimopoulos M" first="Meletios" last="Dimopoulos">Meletios Dimopoulos</name><affiliation><nlm:affiliation>Department of Therapeutics, University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Jagannath, Sundar" sort="Jagannath, Sundar" uniqKey="Jagannath S" first="Sundar" last="Jagannath">Sundar Jagannath</name><affiliation><nlm:affiliation>Mount Sinai Medical Center, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation><nlm:affiliation>Universitätsklinikum Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:affiliation>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L" last="Kaufman">Jonathan L. Kaufman</name><affiliation><nlm:affiliation>Emory University School of Medicine, Atlanta, GA.</nlm:affiliation></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation><nlm:affiliation>Service des Maladies du Sang, University of Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name><affiliation><nlm:affiliation>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation><nlm:affiliation>Universitair Ziekenhuis Gent, Ghent, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Eid, Joseph E" sort="Eid, Joseph E" uniqKey="Eid J" first="Joseph E" last="Eid">Joseph E. Eid</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Houp, Jennifer" sort="Houp, Jennifer" uniqKey="Houp J" first="Jennifer" last="Houp">Jennifer Houp</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Gause, Christine" sort="Gause, Christine" uniqKey="Gause C" first="Christine" last="Gause">Christine Gause</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Vuocolo, Scott" sort="Vuocolo, Scott" uniqKey="Vuocolo S" first="Scott" last="Vuocolo">Scott Vuocolo</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C" last="Anderson">Kenneth C. Anderson</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27025160</idno><idno type="pmid">27025160</idno><idno type="doi">10.1016/j.clml.2016.02.042</idno><idno type="wicri:Area/PubMed/Corpus">001D35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.</title><author><name sortKey="Siegel, David S" sort="Siegel, David S" uniqKey="Siegel D" first="David S" last="Siegel">David S. Siegel</name><affiliation><nlm:affiliation>Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org.</nlm:affiliation></affiliation></author><author><name sortKey="Dimopoulos, Meletios" sort="Dimopoulos, Meletios" uniqKey="Dimopoulos M" first="Meletios" last="Dimopoulos">Meletios Dimopoulos</name><affiliation><nlm:affiliation>Department of Therapeutics, University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Jagannath, Sundar" sort="Jagannath, Sundar" uniqKey="Jagannath S" first="Sundar" last="Jagannath">Sundar Jagannath</name><affiliation><nlm:affiliation>Mount Sinai Medical Center, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation><nlm:affiliation>Universitätsklinikum Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:affiliation>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L" last="Kaufman">Jonathan L. Kaufman</name><affiliation><nlm:affiliation>Emory University School of Medicine, Atlanta, GA.</nlm:affiliation></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation><nlm:affiliation>Service des Maladies du Sang, University of Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name><affiliation><nlm:affiliation>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation><nlm:affiliation>Universitair Ziekenhuis Gent, Ghent, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Eid, Joseph E" sort="Eid, Joseph E" uniqKey="Eid J" first="Joseph E" last="Eid">Joseph E. Eid</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Houp, Jennifer" sort="Houp, Jennifer" uniqKey="Houp J" first="Jennifer" last="Houp">Jennifer Houp</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Gause, Christine" sort="Gause, Christine" uniqKey="Gause C" first="Christine" last="Gause">Christine Gause</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Vuocolo, Scott" sort="Vuocolo, Scott" uniqKey="Vuocolo S" first="Scott" last="Vuocolo">Scott Vuocolo</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C" last="Anderson">Kenneth C. Anderson</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical lymphoma, myeloma & leukemia</title><idno type="eISSN">2152-2669</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bortezomib (administration & dosage)</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Hydroxamic Acids (administration & dosage)</term><term>Male</term><term>Multiple Myeloma (drug therapy)</term><term>Multiple Myeloma (mortality)</term><term>Multiple Myeloma (pathology)</term><term>Recurrence</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bortezomib</term><term>Hydroxamic Acids</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Male</term><term>Recurrence</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27025160</PMID><DateCreated><Year>2016</Year><Month>06</Month><Day>17</Day></DateCreated><DateCompleted><Year>2017</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma & leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.</ArticleTitle><Pagination><MedlinePgn>329-334.e1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clml.2016.02.042</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2152-2650(16)00102-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents.</AbstractText><AbstractText Label="PATIENTS AND METHODS">Eligible patients were age ≥ 18 years, had received ≥ 2 previous regimens, had disease refractory to ≥ 1 previous bortezomib-containing regimen, and had received ≥ 1 dose of an immunomodulatory drug (thalidomide or lenalidomide)-based regimen. The patients received 21-day cycles of bortezomib (1.3 mg/m(2) intravenously on days 1, 4, 8, and 11) plus oral vorinostat (400 mg/d on days 1-14). Oral dexamethasone, 20 mg, on the day of and the day after each dose of bortezomib could be added for patients with progressive disease after 2 cycles or no change after 4 cycles. The primary endpoint was the objective response rate.</AbstractText><AbstractText Label="RESULTS">The objective response rate was 11.3% (95% confidence interval, 6.6%-17.7%), and the median duration of response was 211 days (range, 64-550 days). The median overall survival duration was 11.2 months (95% confidence interval, 8.5-14.4 months), with a 2-year survival rate of 32%. The frequently reported adverse events were thrombocytopenia (69.7%), nausea (57.0%), diarrhea (53.5%), anemia (52.1%), and fatigue (48.6%); the overall safety profile was consistent with that of bortezomib and vorinostat.</AbstractText><AbstractText Label="CONCLUSION">The combination of vorinostat and bortezomib is active in patients with multiple myeloma refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (ClinicalTrials.gov identifier, NCT00773838).</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>Meletios</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Therapeutics, University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagannath</LastName><ForeName>Sundar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mount Sinai Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldschmidt</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Universitätsklinikum Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durrant</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leleu</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Service des Maladies du Sang, University of Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagler</LastName><ForeName>Arnon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Offner</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universitair Ziekenhuis Gent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graef</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houp</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gause</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuocolo</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00773838</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>58IFB293JI</RegistryNumber><NameOfSubstance UI="C111237">vorinostat</NameOfSubstance></Chemical><Chemical><RegistryNumber>69G8BD63PP</RegistryNumber><NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Combination therapy</Keyword><Keyword MajorTopicYN="Y">Efficacy</Keyword><Keyword MajorTopicYN="Y">Histone deacetylase inhibitor</Keyword><Keyword MajorTopicYN="Y">Proteasome inhibitor</Keyword><Keyword MajorTopicYN="Y">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27025160</ArticleId><ArticleId IdType="pii">S2152-2650(16)00102-6</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2016.02.042</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27025160
|texte= VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27025160" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |